The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.95
Bid: 4.80
Ask: 5.10
Change: 0.00 (0.00%)
Spread: 0.30 (6.25%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4.95
SEE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity to raise £1.272m Replacement

26 Oct 2012 11:55

RNS Number : 6502P
Seeing Machines Limited
26 October 2012
 



26 October 2012

 

The following amendments have been made to the 'Issue of Equity to Raise £1.272 million' announcement released on 19 October 2012 at 12:37 pm under RNS No 1147P.

 

In the table titled "Significant and Substantial Shareholdings Post Placing", the Australian National University's figure for shares held was 38,226,073 and their percentage shareholdingwas 8.01%. These figures were incorrect and should have been 20,000,000 shares held and a percentage holding of 4.19%. Further, in the same table, Roy Nominees Ltd was added in as an individual shareholder when this was in fact a duplication of the RBC Trusts' shareholding. Accordingly, this has now been removed.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

 

19 October 2012

 

Seeing Machines Limited

('Seeing Machines' or 'the Company')

 

ISSUE OF EQUITY TO RAISE £1.272 MILLION

 

Seeing MachinesLimited (AIM:SEE)is pleased to announce that it has raised gross proceeds of £1.272m through the issue of 63,582,803 new Ordinary Shares (the 'Placing Shares') to institutional and other investors in the UK and Australia, at a price of 2.0 pence per share (the 'Placing Price') (together 'the Placing'). The Placing Price represents a fourteen per cent. premium to the closing share price on 18 October 2012, being the latest practicable day prior to the date of this announcement.

 

Application has been made for the Placing Shares to be admitted to AIM and admission is expected to take place on or about 22 October 2012.

 

The proceeds of the Placing will be used to enable Seeing Machines to:

a. increase its inventory of DSS products to bring forward revenue resulting from new contracts being signed;

b. invest in a new fully outsourced manufacturing process that is highly scalable and capable of meeting current forecast demand; and

c. recruit additional R&D resources to enable the Company to deliver against contracts being negotiated with the auto industry and to recruit experienced general management with mining domain expertise.

 

Following the Placing, the Company will have 477,221,682 Ordinary shares in issue, all of which will carry voting rights. This figure may be used by shareholders of the Company as the denominator for calculations by which they will determine if they are required to notify their interest in, or change their interest in, the ordinary share capital of the Company under the FSA's Disclosure and Transparency Rules.

 

Commenting on the Placing Results, Seeing Machines Chairman, Terry Winters said:

"I am delighted to announce that Seeing Machines has raised nearly £1.3m at a fourteen per cent. premium to the Company's current share price. This placing follows on from the excellent progress the Company has made in the last few months in winning major new contracts within the mining sector."

 

Following the issue of the Placing Shares, the relevant share holdings of directors, connected persons, substantial and significant shareholdings as defined in the AIM Rules for Companies will be as follows:

 

Directors and Connected Persons Shareholdings

Shareholder

Note

Post-Placing

Shares Held

Post-Placing

% Shareholding

Alexander Zelinsky

22,244,810

4.66%

Rob Sale

1

5,747,740

1.20%

David Gaul

2

3,111,173

0.65%

Ken Kroeger

3

1,592,357

0.33%

Terry Winters

1,632,166

0.34%

 

1. Rob Sale's 2,745,715 shares are held in the name of Caffe Pty Ltd ATF the R C Sale Superannuation Fund and there are also 2,621,369 shares held by Rob's wife Paula Kay Sale and 380,386 held in his own name.

2. David Gaul holds 3,111,173 shares through his company Jaiclimb Pty Limited.

3. Ken Kroeger's 1,592,357 shares are held in the name of Insperience Pty Ltd.

 

 

Significant and Substantial Shareholdings Post Placing

Shareholder

Shares Held

% shareholding

RBC Trusts

85,415,496

17.90%

Volvo Technology Transfer AB (held in the name of HSBC Global Custody Nominee (UK) Limited

50,732,709

10.63%

Sebastien Rougeaux

23,139,509

4.85%

Alexander Zelinsky

22,244,810

4.66%

Chase Nominees Limited

22,152,400

4.64%

Timothy Edwards

21,849,855

4.58%

Jochen Heinzmann

21,448,632

4.49%

Australian National University

20,000,000

4.19%

 

 

 

For further information, please contact:

 

Seeing Machines Limited

Ken Kroeger, CEO

+61 2 6103 4700

Ken.Kroeger@seeingmachines.com

Terry Winters, Chairman

+61 411 411 111

Terry.Winters@seeingmachines.com

Daniel Stewart & Company plc.

David Hart / James Thomas

+44 20 7776 6550

Walbrook PR

Helen Westaway

Paul Cornelius

 

+44 20 7933 8790

Helen.Westaway@walbrookpr.com

+44 20 7933 8794

Paul.Cornelius@walbrookir.com

 

About Seeing Machines Limited

Seeing Machines is a world-leader in computer vision processing technologies and the application of this technology in global high value, high growth markets. The companyis recognised globally for its leading development of premier products and applications that rely on capturing and understanding the behaviour of human faces and eyes. More information is available from our web site: www.seeingmachines.com

About Seeing Machines' Driver Safety Solution (DSS)

The Seeing Machines DSS suite is a rugged, non-invasive platform that uses cutting edge face and eye tracking techniques to deliver information on operator fatigue and distraction. The DSS has been specifically designed for deployment into fleets and environments where fatigue and operator distraction pose substantial risk to personnel and equipment and therefore need to be monitored and managed.

For more information on DSS, go to http://www.seeingmachines.com/product/dss/

About Seeing Machines' faceAPI®

faceAPI® allows users to incorporate Seeing Machines world-class face tracking technology into their own products or applications. faceAPI provides a growing suite of image-processing modules created specifically for tracking and understanding faces and facial features. These powerful tracking modules are combined into a complete API toolkit that delivers a rich stream of information that can be incorporated into our customers' own products or services. Seeing Machines faceAPI® delivers a comprehensive, integrated solution for developing products that leverage real-time face tracking. All image-processing for face tracking is handled internally, removing the need for computer vision experience.For more information on faceAPI®, go to http://www.seeingmachines.com/product/faceapi/

About Seeing Machines' faceLAB®5

Seeing Machines has been creating advanced eye tracking algorithms since the company was founded in 2000. faceLAB®5 is the organisation's eye tracking system that allows researchers to objectively measure human behavior in a wide range of operational conditions and research settings. faceLAB®'s unique eye and facial tracking solution offers users rare flexibility, portability, and accuracy.

For more information on faceLAB®, go to http://www.seeingmachines.com/product/facelab/

About Seeing Machines' Truefield® Analyzer (TFA)

Currently going through its final clinical trials, the TFA will make objective visual field testing a clinical reality. It combines objectivity with 'non-contact' ease of use, making it easy for technicians and patients, giving clinicians objectivity when assessing their patients' conditions. Assessing both eyes concurrently, TFA tests are fast and can be run in both full-test and screening modes. The tests' bilateral concurrency allows the consensual light reflex to be exploited to identify bilateral asymmetries improving test accuracy. Most importantly, the TFA makes objective perimetry a clinical reality.

For more information on TFA, go to http://www.seeingmachines.com/product/truefield/

About Seeing Machines' Fatigue Management Consulting

Seeing Machines supports its DSS technology with professional and scientific fatigue management consulting and training services designed to build understanding of how businesses can reduce the risk of operator fatigue and support the readiness, implementation and acceptance of its products. Seeing Machines has developed a comprehensive fatigue management framework through combined collaboration with leading fatigue research institutions and hands on experience in the field with organisations who proactively manage fatigue. Seeing Machines also provides detailed fatigue management training for site personnel to better enable them to understand the causes of, and manage their own fatigue.

For more information on fatigue management, go to http://www.seeingmachines.com/fatigue-consultancy/ 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEFELFSMFESEIS
Date   Source Headline
23rd Aug 201812:02 pmRNSTransfer of Ordinary Shares
16th Aug 201811:09 amRNSHolding(s) in Company
15th Aug 20189:41 amRNSIssue of Shares for Vested Performance Rights
9th Aug 20187:00 amRNSSeeing Machines leads pilot training collaboration
3rd Aug 20187:00 amRNSYear end trading update
27th Jul 20187:00 amRNSOEM Design Award
16th Jul 20187:00 amRNSBoard changes
5th Jul 20187:00 amRNSUS Fleet (Guardian) Contract
28th Jun 20181:27 pmRNSHolding(s) in Company
15th Jun 201810:43 amRNSKey Staff Recognised
7th Jun 201811:05 amRNSSecond Price Monitoring Extn
7th Jun 201811:00 amRNSPrice Monitoring Extension
5th Jun 201811:05 amRNSSecond Price Monitoring Extn
5th Jun 201811:00 amRNSPrice Monitoring Extension
4th Jun 20187:00 amRNSAutomotive design win with US OEM for FOVIO chip
21st May 20187:00 amRNSBusiness Outlook Update
18th May 201810:14 amRNSEuropean Commission Agenda Affirms SEE Tech
17th May 20184:40 pmRNSSecond Price Monitoring Extn
17th May 20184:35 pmRNSPrice Monitoring Extension
16th May 20187:00 amRNSAustralian Distributor Expands Guardian Commitment
9th May 20184:40 pmRNSSecond Price Monitoring Extn
9th May 20184:35 pmRNSPrice Monitoring Extension
26th Apr 20187:08 amRNSAutomotive Design Award with Premium German OEM
12th Apr 20187:00 amRNSChange of Adviser
12th Mar 20187:00 amRNSHalf Year Results to 31 December 2017
9th Mar 20187:52 amRNSStatement regarding Press Speculation
28th Feb 20187:00 amRNSNotice of Results & Investor Events
22nd Feb 20188:13 amRNSHolding(s) in Company
22nd Feb 20188:00 amRNSBlock Listing Cancellation
21st Feb 20189:00 amRNSDirectorate Change Update
8th Feb 20187:00 amRNSTrading Update & Fleet, Rail and Off-Road Update
29th Jan 20187:00 amRNSDirectorate Change
23rd Jan 201810:54 amRNSHolding(s) in Company
16th Jan 20189:22 amRNSResult of Offer and Total Voting Rights
9th Jan 201810:44 amRNSHolding(s) in Company
8th Jan 20189:23 amRNSHolding(s) in Company
3rd Jan 20188:44 amRNSResult of General Meeting and Total Voting Rights
22nd Dec 20177:00 amRNSBlock Listing Return and Total Voting Rights
5th Dec 20173:57 pmRNSSuccessful Placing and Subscriptions to raise £35m
4th Dec 20175:33 pmRNSProposed Accelerated Bookbuild
30th Nov 20177:00 amRNSDubai Distributor Wins Guardian Contracts in 2017
17th Nov 20177:01 amRNSResult of AGM
17th Nov 20177:00 amRNSAGM Statement
2nd Nov 201710:02 amRNSIssue of Shares to Directors and Staff & TVR
30th Oct 20177:00 amRNSNew DMS Program Award
25th Oct 20179:00 amRNSHolding(s) in Company
25th Oct 20177:00 amRNSEmirates and Seeing Machines Collaboration
24th Oct 20177:00 amRNSEuro NCAP and NTSB - Driver Monitoring Systems
23rd Oct 20177:00 amRNSNotice of AGM
17th Oct 201712:40 pmRNSBusiness Outlook Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.